Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin | Zendy

Qing Liu | Zendy; Hongbo He | Zendy; Yuhao Yuan | Zendy; Hao Zeng | Zendy; Zhiwei Wang | Zendy; Wei Luo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel Expression of EGFL7 in Osteosarcoma and Sensitivity to Cisplatin

Author(s) -

Qing Liu,

Hongbo He,

Yuhao Yuan,

Hao Zeng,

Zhiwei Wang,

Wei Luo

Publication year - 2020

Publication title -

frontiers in oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.834

H-Index - 83

ISSN - 2234-943X

DOI - 10.3389/fonc.2020.00074

Subject(s) - osteosarcoma , cisplatin , cancer research , sensitivity (control systems) , medicine , computer science , oncology , chemotherapy , engineering , electronic engineering

Epidermal growth factor-like domain 7 (EGFL7) is a protein specifically secreted by blood vessel endothelial cells, which plays an important role in angiogenesis. Considering the aberrant secretion of EGFL7 in osteosarcoma (OS) has not yet been elucidated, this study investigated the secretion of EGFL7 in OS and the changes in its secretion after chemotherapy. We observed increased varying secretion of EGFL7 in OS tissues compared with chondrosarcoma (CS) tissues. OS cell lines and HUVECs showed higher EGFL7 mRNA and protein expression than SW1353, with OS cells expressing the highest levels. In patient samples, EGFL7 was highly expressed in the cytoplasm of OS tumor cells and vascular endothelium cells. This overexpression was abolished in OS cell and tumor tissues when treated with chemotherapy. This study is a pioneering study to investigate EGFL7 expression and localization in human OS tissues and cell. Overexpression of EGFL-7 in response to chemotherapy suggests that it can be used as a therapeutic target for OS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research